Seeking to extend the reign of cancer king Keytruda, Merck has shown that a subcutaneous version of the anti-PD-1 therapy performs as well as the more invasive infusion formulation in a Phase III ...

A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be in the works from Korea’s Alteogen following a licensing deal worth ...